Orgenesis Inc. (ORGS) |
| 0.575 0.025 (4.55%) 02-25 10:14 |
| Open: | 0.575 |
| High: | 0.575 |
| Low: | 0.575 |
| Volume: | 110 |
| Market Cap: | 3(M) |
| PE Ratio: | -0.02 |
| Exchange: | Other OTC |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.06 |
| Resistance 1: | 0.91 |
| Pivot price: | 0.64 |
| Support 1: | 0.44 |
| Support 2: | 0.15 |
| 52w High: | 5.89 |
| 52w Low: | 0.02 |
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
| EPS | -24050000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 69.071 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -2.00 |
| Return on Assets (ttm) | 196.3 |
| Return on Equity (ttm) | -68.5 |
Tue, 10 Feb 2026
The Truth About Orgenesis Inc (ORGS): Tiny Biotech, Huge Hype – But Is It Worth Your Money? - AD HOC NEWS
Mon, 26 Jan 2026
Orgenesis Signs Warrant Issuance Agreement With Alpha Prosperity Fund - TradingView
Fri, 05 Sep 2025
Orgenesis’s Sharp Swings Define Its High-Risk Biotech Story - Finimize
Tue, 19 Aug 2025
Orgenesis announces resignation of CFO and three board members - Investing.com
Thu, 17 Oct 2024
Orgenesis Inc. to be delisted from Nasdaq - Investing.com
Fri, 30 Aug 2024
Orgenesis’ CAR-T ORG-101 Demonstrates Efficacy and Safety in Acute Lymphoblastic Leukemia in Real-World Study in China - CGTLive®
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |